AR037284A1 - Compuestos derivados de 1,2,4-tiadiazol-2-io, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones - Google Patents
Compuestos derivados de 1,2,4-tiadiazol-2-io, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composicionesInfo
- Publication number
- AR037284A1 AR037284A1 ARP020104271A ARP020104271A AR037284A1 AR 037284 A1 AR037284 A1 AR 037284A1 AR P020104271 A ARP020104271 A AR P020104271A AR P020104271 A ARP020104271 A AR P020104271A AR 037284 A1 AR037284 A1 AR 037284A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- heterocycloalkyl
- alkenyl
- alkynyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000000304 alkynyl group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000003944 tolyl group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 201000004700 rosacea Diseases 0.000 abstract 2
- -1 1,2,4-thiadiazol-2-io Chemical class 0.000 abstract 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010050337 Cerumen impaction Diseases 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 208000001840 Dandruff Diseases 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 206010013786 Dry skin Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010016936 Folliculitis Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical group CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
- 102000004378 Melanocortin Receptors Human genes 0.000 abstract 1
- 108090000950 Melanocortin Receptors Proteins 0.000 abstract 1
- 229910002651 NO3 Inorganic materials 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical group [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 206010072139 Ocular rosacea Diseases 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 241001303601 Rosacea Species 0.000 abstract 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 150000001649 bromium compounds Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 210000002939 cerumen Anatomy 0.000 abstract 1
- 125000000068 chlorophenyl group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000001177 diphosphate Chemical group 0.000 abstract 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical group [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 210000004907 gland Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 208000002557 hidradenitis Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 229940049920 malate Drugs 0.000 abstract 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical group OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 abstract 1
- 210000004175 meibomian gland Anatomy 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 208000020469 nerve plexus disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Chemical group 0.000 abstract 1
- 201000006380 plexopathy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009759 skin aging Effects 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical group [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4018—Esters of cycloaliphatic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Compuestos derivados de 1,2,4-tiadiazol-2-io de fórmula (1), en donde: R1 se selecciona del grupo que consiste en arilo, aralquilo, heteroarilo, heteroarilo-alquilo, heterocicloalquilo, heterocicloalquilo-alquilo, cicloalquilo y cicloalquilo-alquilo; en donde el grupo arilo, aralquilo, heteroarilo, heterocicloalquilo, heterocicloalquilo-alquilo o cicloalquilo se puede sustituir de manera opcional por uno o más sustituyentes seleccionados de manera independiente de halógeno, hidroxi, alquilo, alcoxi, alquilo halogenado, alcoxi halogenado, amino, alquilamino o di(alquil)amino; R2 se selecciona del grupo que consiste en arilo, aralquilo, heteroarilo, heterocicloalquilo y cicloalquilo-alquilo; en donde el grupo arilo, aralquilo, heteroarilo, heterocicloalquilo o cicloalquilo se puede sustituir de manera opcional por uno o más sustituyentes seleccionados de manera independiente de halógeno, hidroxi, alquilo, alcoxi, alquilo halogenado, alcoxi halogenado, amino, alquilamino o di(alquil)amino; R3 se selecciona del grupo que consiste en hidrógeno, alquilo, alquenilo y alquinilo; en donde el enlace doble del alquenilo o el enlace triple del grupo alquinilo está por lo menos un átomo de carbono alejado del punto de unión; R4 se selecciona del grupo que consiste en arilo, aralquilo, heteroarilo, heterocicloalquilo y cicloalquilo-alquilo; en donde el grupo arilo, aralquilo, heteroarilo, heterocicloalquilo o cicloalquilo se puede sustituir de manera opcional por uno o más sustituyentes seleccionados de manera independiente de halógeno, hidroxi, alquilo, alcoxi, alquilo halogenado, alcoxi halogenado, amino, alquilamino o di(alquil)amino; X se selecciona del grupo que consiste en bromuro, cloruro, yoduro, acetato, benzoato, citrato, lactato, malato, nitrato, fosfato, difosfato, succinato, sulfato, tartrato, y tosilato; siempre que cuando R1 sea fenilo, o clorofenilo o bencilo, R2 sea fenilo, o benzotienilo y R4 sea fenilo o aralquilo, entonces R3 se selecciona del grupo que consiste en alquilo, alquenilo, y alquinilo; en donde el enlace doble del alquenilo o el enlace triple del grupo alquinilo está por lo menos un átomo de carbono alejado del punto de unión; siempre también que cuando R1 sea bencilo o metilfenilo, R2 sea fenilo o metilfenilo y R4 sea metilfenilo o 4-metoxifenilo, entonces R3 se selecciona del grupo que consiste en alquilo, alquenilo, y alquinilo; en donde el enlace doble del alquenilo o el enlace triple del grupo alquinilo está por lo menos un átomo de carbono alejado del punto de unión; siempre también que cuando R1 sea fenilo, R2 sea fenilo y R4 sea fenilo, entonces R3 se selecciona del grupo que consiste en alquilo C3-8 (es decir, no metilo o etilo), alquenilo y alquinilo; preferentemente, R3 se selecciona del grupo que consiste en alquenilo y alquinilo; en donde el enlace doble del alquenilo o el enlace triple del grupo alquinilo está por lo menos un átomo de carbono alejado del punto de unión; y sales farmacéuticamente aceptables del mismo. Dichos compuestos son útiles como agonistas o antagonistas del receptor de melanocortina Más particularmente, estos compuestos son útiles para el tratamiento de trastornos metabólicos, del SNC y dermatológicos, tales como obesidad, intolerancia oral a la glucosa, niveles elevados de glucosa en sangre, diabetes de tipo II, síndrome X, retinopatía diabética, lesiones de la médula espinal, lesiones en los nervios, trastornos neurodegenerativos agudos, trastornos neurodegenerativos crónicos, plexopatías, disfunción eréctil masculina, ojos secos, acné, sequedad en la piel, envejecimiento de la piel, dermatitis seborreica, rosácea, excesiva cera en los oídos, trastornos en la glándula de Meibomio, pseudofoliculitis, infecciones por levadura, caspa, hidradenitis supurativa, rosácea ocular y trastornos de la glándula ecrina. También se dan a conocer, composiciones farmacéuticas que los comprenden, y un método para preparar dichas composiciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33776201P | 2001-11-08 | 2001-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037284A1 true AR037284A1 (es) | 2004-11-03 |
Family
ID=23321888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104271A AR037284A1 (es) | 2001-11-08 | 2002-11-07 | Compuestos derivados de 1,2,4-tiadiazol-2-io, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US7319107B2 (es) |
| EP (1) | EP1444215B1 (es) |
| JP (1) | JP4491235B2 (es) |
| CN (1) | CN100422164C (es) |
| AR (1) | AR037284A1 (es) |
| AT (1) | ATE333449T1 (es) |
| AU (1) | AU2002340372B2 (es) |
| BR (1) | BR0214023A (es) |
| CA (1) | CA2466145A1 (es) |
| CY (1) | CY1105233T1 (es) |
| DE (1) | DE60213276T2 (es) |
| DK (1) | DK1444215T3 (es) |
| ES (1) | ES2268108T3 (es) |
| IL (2) | IL161830A0 (es) |
| MX (1) | MXPA04004457A (es) |
| MY (1) | MY134994A (es) |
| NO (1) | NO328194B1 (es) |
| NZ (1) | NZ532884A (es) |
| PT (1) | PT1444215E (es) |
| RS (1) | RS51199B (es) |
| RU (1) | RU2323932C2 (es) |
| SI (1) | SI1444215T1 (es) |
| TW (1) | TWI317358B (es) |
| WO (1) | WO2003040118A1 (es) |
| ZA (1) | ZA200404487B (es) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| WO2003040117A1 (en) * | 2001-11-08 | 2003-05-15 | Ortho-Mcneil Pharmaceutical Corporation | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US8460243B2 (en) * | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| CA2557144A1 (en) * | 2004-02-23 | 2005-09-09 | Prolexys Pharmaceuticals Inc. | Non-peptidyl agents with phsp20-like activity, and uses thereof |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| WO2005119524A2 (en) | 2004-06-04 | 2005-12-15 | Therasense, Inc. | Diabetes care host-client architecture and data management system |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| WO2013003594A2 (en) | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
| US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| US20090043365A1 (en) * | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
| US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US7981146B2 (en) * | 2006-05-15 | 2011-07-19 | Tearscience Inc. | Inner eyelid treatment for treating meibomian gland dysfunction |
| US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
| US20070016256A1 (en) * | 2005-07-18 | 2007-01-18 | Korb Donald R | Method and apparatus for treating gland dysfunction |
| US7981095B2 (en) * | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
| US8007524B2 (en) * | 2006-05-15 | 2011-08-30 | Tearscience, Inc. | Heat treatment and heat loss reduction for treating meibomian gland dysfunction |
| US8128673B2 (en) * | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US8527313B2 (en) * | 2006-05-15 | 2013-09-03 | Sap Ag | Document instantiation triggering a business action |
| US7981147B2 (en) * | 2006-05-15 | 2011-07-19 | Tearscience, Inc. | Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
| US7976573B2 (en) * | 2006-05-15 | 2011-07-12 | Tearscience, Inc. | Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US8137390B2 (en) * | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
| US8128674B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| WO2008027069A1 (en) * | 2006-08-21 | 2008-03-06 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction employing fluid |
| USD613408S1 (en) | 2008-02-06 | 2010-04-06 | Tearscience, Inc. | Eye treatment head gear |
| USD617443S1 (en) | 2008-02-06 | 2010-06-08 | Tearscience, Inc. | Eye treatment goggles |
| ES2453640T3 (es) | 2008-02-21 | 2014-04-08 | Janssen Pharmaceutica N.V. | Métodos para el tratamiento de desordenes dermatológicos |
| US8377925B2 (en) | 2008-02-29 | 2013-02-19 | Mimetica Pty Ltd | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor |
| US8008291B2 (en) * | 2008-02-29 | 2011-08-30 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists |
| US8343958B2 (en) | 2008-02-29 | 2013-01-01 | Mimetica Pty Ltd | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists |
| EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES |
| US8877776B2 (en) | 2009-01-16 | 2014-11-04 | Exelixis, Inc. | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| BRPI1013853A2 (pt) * | 2009-04-24 | 2019-09-24 | Janssen Pharmaceuticals Inc | composições tópicas estáveis de derivados de 1,2,4-tiadiazol |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| ES2360783B1 (es) * | 2009-10-02 | 2012-07-04 | Consejo Superior De Investigaciones Científicas (Csic) | 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas |
| USD638128S1 (en) | 2009-10-06 | 2011-05-17 | Tearscience, Inc. | Ocular device design |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| EP2568812B1 (en) | 2010-05-11 | 2016-10-26 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| EP2628734A4 (en) * | 2010-10-15 | 2014-04-23 | Federalnoe G Bydzhetnoe Uchrezhdenie Nauki Inst Fiziol Aktivnikh Veschestv Rossiiskoi Akademii Nauk | DERIVATIVES OF 5-AMINO - [1,2,4] THIADIAZOLE |
| US9018395B2 (en) | 2011-01-27 | 2015-04-28 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| ES2868231T3 (es) * | 2011-03-07 | 2021-10-21 | Amgen Europe Gmbh | Métodos de tratamiento de enfermedades usando compuestos de isoindolina |
| WO2013102047A1 (en) | 2011-12-29 | 2013-07-04 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
| US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
| EP3424558B1 (en) | 2013-04-30 | 2020-07-22 | Alcon Inc. | Systems for the treatment of eye conditions |
| US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
| US10265348B2 (en) | 2014-10-31 | 2019-04-23 | Lipotec S.A.U. | Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof |
| FI3356386T3 (fi) | 2015-09-30 | 2024-05-16 | Rhythm Pharmaceuticals Inc | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä |
| US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
| EP3773897A1 (en) | 2018-04-06 | 2021-02-17 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
| CN115381955B (zh) * | 2021-05-24 | 2024-05-17 | 中国科学技术大学 | 黑皮质素受体mc5r的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE131373C (es) | ||||
| DD131373A1 (de) | 1977-06-17 | 1978-06-21 | Juergen Liebscher | Verfahren zur herstellung von 2,3-disubstituierten 5-dialkylamino-1,2,4-thiadiazoliumsalzen |
| JPS6011481A (ja) | 1983-06-30 | 1985-01-21 | Nippon Soda Co Ltd | １，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤 |
| JPH02173165A (ja) | 1988-12-27 | 1990-07-04 | Nippon Soda Co Ltd | 防汚剤 |
| DK0805153T3 (da) * | 1996-04-30 | 2002-03-18 | Pfizer | Hidtil ukendte muskarine receptoragonister |
| US20020103194A1 (en) * | 1997-04-30 | 2002-08-01 | Anabella Villalobos | Novel muscarinic receptor agonists |
| EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| CN1111523C (zh) | 1998-04-29 | 2003-06-18 | 阿克西瓦有限公司 | 催化制备取代的联吡啶衍生物的方法 |
| JP2002517444A (ja) | 1998-06-11 | 2002-06-18 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作動薬としてのスピロピペリジン誘導体 |
| US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| AU1324300A (en) | 1998-10-26 | 2000-05-15 | Vertex Pharmaceuticals Incorporated | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase |
| AU2001228681A1 (en) | 2000-01-28 | 2001-08-07 | Melacure Therapeutics Ab | Novel aromatic amines and amides acting on the melanocortin receptors |
| AU4928101A (en) * | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Spiropiperidine derivatives as melanocortin receptor agonists |
| US6728804B1 (en) | 2000-10-27 | 2004-04-27 | Emware, Inc. | Remotely reprogrammable communications adapter for providing access to an electronic device |
| US7319107B2 (en) * | 2001-11-08 | 2008-01-15 | Johnson & Johnson Consumer Companies, Inc. | 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators |
| WO2003040117A1 (en) * | 2001-11-08 | 2003-05-15 | Ortho-Mcneil Pharmaceutical Corporation | Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| US7435429B2 (en) * | 2002-02-07 | 2008-10-14 | Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
| ES2453640T3 (es) * | 2008-02-21 | 2014-04-08 | Janssen Pharmaceutica N.V. | Métodos para el tratamiento de desordenes dermatológicos |
| BRPI1013853A2 (pt) * | 2009-04-24 | 2019-09-24 | Janssen Pharmaceuticals Inc | composições tópicas estáveis de derivados de 1,2,4-tiadiazol |
-
2002
- 2002-11-04 US US10/287,096 patent/US7319107B2/en not_active Expired - Fee Related
- 2002-11-05 EP EP02778727A patent/EP1444215B1/en not_active Expired - Lifetime
- 2002-11-05 NZ NZ532884A patent/NZ532884A/en not_active IP Right Cessation
- 2002-11-05 SI SI200230407T patent/SI1444215T1/sl unknown
- 2002-11-05 RS YUP-396/04A patent/RS51199B/sr unknown
- 2002-11-05 RU RU2004114208/04A patent/RU2323932C2/ru not_active IP Right Cessation
- 2002-11-05 BR BR0214023-3A patent/BR0214023A/pt active Search and Examination
- 2002-11-05 AU AU2002340372A patent/AU2002340372B2/en not_active Ceased
- 2002-11-05 PT PT02778727T patent/PT1444215E/pt unknown
- 2002-11-05 CN CNB028268989A patent/CN100422164C/zh not_active Expired - Fee Related
- 2002-11-05 DK DK02778727T patent/DK1444215T3/da active
- 2002-11-05 ES ES02778727T patent/ES2268108T3/es not_active Expired - Lifetime
- 2002-11-05 IL IL16183002A patent/IL161830A0/xx unknown
- 2002-11-05 WO PCT/US2002/035365 patent/WO2003040118A1/en active IP Right Grant
- 2002-11-05 DE DE60213276T patent/DE60213276T2/de not_active Expired - Lifetime
- 2002-11-05 AT AT02778727T patent/ATE333449T1/de active
- 2002-11-05 JP JP2003542164A patent/JP4491235B2/ja not_active Expired - Fee Related
- 2002-11-05 MX MXPA04004457A patent/MXPA04004457A/es active IP Right Grant
- 2002-11-05 CA CA002466145A patent/CA2466145A1/en not_active Abandoned
- 2002-11-07 AR ARP020104271A patent/AR037284A1/es not_active Application Discontinuation
- 2002-11-08 TW TW091133318A patent/TWI317358B/zh not_active IP Right Cessation
- 2002-11-08 MY MYPI20024180A patent/MY134994A/en unknown
-
2004
- 2004-05-06 IL IL161830A patent/IL161830A/en not_active IP Right Cessation
- 2004-06-07 ZA ZA200404487A patent/ZA200404487B/en unknown
- 2004-06-07 NO NO20042373A patent/NO328194B1/no not_active IP Right Cessation
-
2005
- 2005-09-27 US US11/236,097 patent/US20060030604A1/en not_active Abandoned
-
2006
- 2006-09-15 CY CY20061101325T patent/CY1105233T1/el unknown
-
2008
- 2008-08-05 US US12/221,900 patent/US7786311B2/en not_active Expired - Fee Related
-
2010
- 2010-07-13 US US12/835,220 patent/US8501791B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037284A1 (es) | Compuestos derivados de 1,2,4-tiadiazol-2-io, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones | |
| AR037331A1 (es) | Compuestos derivados de 1,2,4-tiadiazol sustituidos, composiciones farmaceuticas que los comprenden, y metodo para preparar dichas composiciones | |
| AP1822A (en) | Substituted pyridinones as modulators of P38 MAP kinase. | |
| DK1697370T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| WO2009063202A3 (en) | Use of crth2 antagonist compounds | |
| MXPA04006003A (es) | Derivados del acido fenilpropionico substituidos como agonistas al receptor alfa activado-proliferativo de peroxisoma (ppar) humano. | |
| PT1613315E (pt) | Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias | |
| DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| CY1112772T1 (el) | Μεθοδος για την τροποποιηση κρυσταλλικου σχηματισμου φαρμακου του αλατος μυκοφαινολικου νατριου | |
| RS28004A (en) | Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease | |
| BRPI0517894A (pt) | derivados de 5-hidróxi-benzo tiazol possuindo atividade agonista de adrenorreceptor beta-2 | |
| JP2011520792A5 (es) | ||
| NO20056007L (no) | Dobbel NK1/NK3 antagonister for behandling av schizofreni | |
| TW200738698A (en) | Organic compounds | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| HRP20080689T3 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| RU2010107169A (ru) | Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого | |
| BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
| MX2011010732A (es) | Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer. | |
| NO20063619L (no) | Diarylmetylpiperazinderivater, fremstilling og anvendelse derav | |
| NO20072089L (no) | Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav | |
| SE0301320D0 (sv) | Positive modulators of nicotinic acetylcholine receptors | |
| CR20200619A (es) | Compuestos de cianotriazol y usos de los mismos | |
| NO20052699L (no) | 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser. | |
| MY153733A (en) | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |